Phaseline

Companies › Biotest

Biotest: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Respiratory; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trimodulin (BT588)
Polyclonal immunoglobulin preparation (IgG, IgM, IgA)
IGG, IGM, IGAPhase 3Community-acquired PneumoniaJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05722938Trimodulin (BT588)Phase 3Community-acquired PneumoniaRespiratoryJul 2028

Targets

IGG (1) IGM (1) IGA (1)

Companies with the same targets

–

Companies built like this

Areteia Therapeutics PureTech Renovion Youssef Yammine Kringle Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.